Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and ...

Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion and ...

Late in 2023 I believed that the potential was still there in the case of Pfizer (PFE) after another setback in the pipeline. To see where Pfizer comes from, we really have to create some perspective, ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Activist investment fund Starboard Value took at stake in Pfizer recently, hoping to change its course. Starboard claimed that a pair of former top managers were willing to act as advisors. Those ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...